The Tubulin Inhibitor VERU-111 in Combination With Vemurafenib Provides an Effective Treatment of Vemurafenib-Resistant A375 Melanoma

Melanoma is one of the deadliest skin cancers having a five-year survival rate around 15–20%. An overactivated MAPK/AKT pathway is well-established in BRAF mutant melanoma. Vemurafenib (Vem) was the first FDA-approved BRAF inhibitor and gained great clinical success in treating late-stage melanoma....

Descripción completa

Detalles Bibliográficos
Autores principales: Cui, Hongmei, Wang, Qinghui, Miller, Duane D., Li, Wei
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Frontiers Media S.A. 2021
Materias:
Pharmacology
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8027488/
https://www.ncbi.nlm.nih.gov/pubmed/33841154
http://dx.doi.org/10.3389/fphar.2021.637098

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8027488/
https://www.ncbi.nlm.nih.gov/pubmed/33841154
http://dx.doi.org/10.3389/fphar.2021.637098

Ejemplares similares